Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge - CNBC
Sentiment Mix
Geography
Expert Signals
Global News - Main Feed
source • 1 mention
Politics - Google News US Headlines
source • 1 mention
AI-Generated Claims
Generated from linked receipts; click sources for full context.
GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk.
Supported by 1 story
Sales of Mounjaro, Eli Lilly's diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.
Supported by 1 story
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge CNBCEli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJEli Lilly Q2 2026 earnings beat, raises full-year revenue forecast qz.comLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and CompanyEli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth
Supported by 1 story
Related Events
Shopify Soars As Q2 Operating Profit, Revenue Top Expectations - Investor's Business Daily
Industry • 8/5/2026
Disney's Q3 earnings top estimates on demand for experiences, company exits A+E Media stake - Yahoo Finance
Uncategorized • 8/5/2026
As bank bonuses soar, PE’s biggest firms play catch-up - PitchBook
Uncategorized • 8/5/2026
Veteran analyst rethinks Palantir stock after earnings - thestreet.com
Uncategorized • 8/5/2026
Citadel surges 6% after swoop on Situational Awareness - Financial Times
Uncategorized • 8/5/2026